Abbott Laboratories (ABT) · Oct 21, 2026 · Earnings

Abbott earnings match EPS views as cancer diagnostics scales

In line — Adjusted EPS $1.42 vs ~$1.42 consensus

Abbott’s Q3 earnings matched adjusted EPS expectations and slightly beat revenue views, while Exact Sciences fueled growth but lifted costs and charges.

Abbott is integrating Exact Sciences into a new cancer-diagnostics growth platform while relying on Medical Devices, Libre, and cardiac technologies for organic expansion; the acquisition is also increasing amortization and financing costs.

The quarter was essentially in line, not a clean beat. Adjusted diluted EPS came in at $1.42, exactly matching the published consensus of roughly $1.42, while revenue of $13.013 billion was modestly above the approximately $12.99 billion expectation. Comparable sales growth was 7.0%, showing the underlying business expanded at a healthy but not surprising pace.

$ millions except EPS3Q263Q25Expectation
Net sales$13,013$11,369~$12,990
Adjusted diluted EPS$1.42$1.30~$1.42
GAAP diluted EPS$0.53$0.94—
Comparable sales growth7.0%——
Diagnostics comparable growth6.4%——
Medical Devices comparable growth7.8%——

The growth engine is becoming clearer. Diagnostics reported sales jumped 46.7%, but the more useful comparable figure was 6.4% after including Exact Sciences in the prior-year comparison. Cancer Diagnostics grew 13.8% comparably, while Medical Devices delivered 7.8% comparable growth, led by Electrophysiology and Diabetes Care.

The headline GAAP collapse mostly reflects acquisition and legal costs, but the costs are still real. GAAP EPS fell to $0.53 from $0.94, with $841 million of intangible amortization and approximately $670 million of legal settlements among the specified items. Interest expense also rose to $297 million from $44 million, consistent with the heavier financing burden created by the Exact Sciences transaction.

The filing does not introduce a new full-year earnings target. That leaves the central question unchanged: whether Exact Sciences’ faster growth and Abbott’s product launches can increasingly offset the acquisition’s amortization, interest, integration, and legal-cost drag. Abbott’s recently highlighted pipeline includes Libre Duo, Amulet 360, and TactiFlex Duo, making commercialization and adoption of those products the next operating proof points.

Bottom line: This was a credible growth quarter but not an earnings surprise: revenue edged ahead, adjusted EPS met expectations, and the strategic growth areas are working. The result advances Abbott’s story modestly, while the acquisition-related cost burden remains a material part of it.

What to watch next

Q4 report; U.S. launches of Libre Duo and TactiFlex Duo

Original filing on SEC EDGAR

More Abbott Laboratories news

Abbott earnings match EPS views as cancer diagnostics scales | ABT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.